文献速递糖尿病

SGLT2抑制剂与2型糖尿病患者视网膜静脉阻塞风险:倾向评分匹配队列研究

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study.
PubMed 文献 · Diabetes Care · 2021-01-01

该研究基于韩国国民健康保险服务2014至2017年全国数据,采用活性对照新用户设计和1:1倾向评分匹配,纳入各47369例SGLT2抑制剂新用户与其他降糖药用户。中位随访2.57年,SGLT2抑制剂组视网膜静脉阻塞发生率为2.19/1000人年,其他降糖药组为1.79/1000人年,风险比1.264(95%CI 1.056,1.513)。亚组分析显示年龄≥60岁和eGFR<60 mL/min/1.73 m2者风险更高。

要点

  • SGLT2抑制剂新用户视网膜静脉阻塞风险较其他降糖药用户显著升高(HR 1.264)。
  • 年龄≥60岁及eGFR<60 mL/min/1.73 m2的患者使用SGLT2抑制剂时风险更高。
  • 该研究提示对高龄或合并慢性肾脏病的2型糖尿病患者应关注视网膜静脉阻塞风险。

核心结论

  • 在匹配队列研究中,SGLT2抑制剂使用与视网膜静脉阻塞风险显著增加相关。
  • 老年患者和慢性肾脏病患者发生视网膜静脉阻塞的风险更高。

研究设计与样本

  • 采用活性对照、新用户设计,基于韩国国民健康保险服务2014至2017年全国数据。
  • 经1:1倾向评分匹配,纳入47369例SGLT2抑制剂新用户和47369例其他降糖药用户。
  • 使用Cox比例风险模型估计视网膜静脉阻塞的风险比及95%CI,并进行探索性亚组分析。

主要发现

  • 随访2.57年期间,SGLT2抑制剂组视网膜静脉阻塞发生率为2.19/1000人年,其他降糖药组为1.79/1000人年。
  • SGLT2抑制剂新使用与其他降糖药使用相比,视网膜静脉阻塞风险比为1.264(95%CI 1.056,1.513)。
  • 亚组分析中,年龄和估算肾小球滤过率与SGLT2抑制剂存在显著交互作用;年龄≥60岁和eGFR<60 mL/min/1.73 m2的患者风险比更高。

临床怎么用

  • 对2型糖尿病患者处方SGLT2抑制剂时,应评估视网膜静脉阻塞风险,尤其高龄或合并慢性肾脏病者。
  • 使用SGLT2抑制剂期间,对高风险患者可考虑关注视网膜静脉阻塞相关症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the association between use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and retinal vein occlusion (RVO) using data from the National Health Insurance Service in South Korea. RESEARCH DESIGN AND METHODS: We used an active comparator, new user design, and nationwide data from 2014 to 2017. Based on a 1:1 propensity score match, we included 47,369 new users of SGLT2 inhibitors and 47,369 users of other glucose-lowering drugs (oGLDs). In the matched sample, we used the Cox proportional hazards model to estimate hazard ratios (HRs) with 95% CIs for developing RVO. Based on the main outcome, exploratory subgroup analyses were undertaken. RESULTS: During a follow-up of 2.57 years, the incidence rate of RVO was 2.19 and 1.79 per 1,000 person-years in patients treated with SGLT2 inhibitors and oGLDs, respectively. The new use of SGLT2 inhibitors was associated with an increased risk of RVO compared with oGLD use (HR 1.264 [95% CI 1.056, 1.513]). In the subgroup analyses, a significant interaction with SGLT2 inhibitors was observed for age and estimated glomerular filtration rate (eGFR); the HR for RVO was higher in patients aged ≥60 years and those with eGFR <60 mL/min/1.73 m2 than in others. CONCLUSIONS: In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of RVO. Older patients and those with chronic kidney disease were at higher risk for RVO.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee MK, Kim B, Han K, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study. Diabetes Care. 2021. PMID: 34301735. doi:10.2337/dc20-3133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。